Andrew Sy
Analyst
Jefferies
Equibles does not estimate personal net worth.
About Andrew Sy
Andrew Sy is recorded as Analyst at Jefferies. Andrew Sy has spoken on 4 earnings calls across 3 companies, most recently for Denali Therapeutics Inc. on August 6, 2026. Those appearances were for Axsome Therapeutics, Inc. (AXSM), Denali Therapeutics Inc. (DNLI) and Vanda Pharmaceuticals Inc. (VNDA). The companies whose calls Andrew Sy spoke on are classified in the Healthcare sector.
Andrew Sy on recent calls
“So maybe one more on Hunter you know you're guiding to a strong sales number for Q3 and then And I think in your prepared remarks, the original guidance for an S-shaped curve still seems to hold.”
“You know, now with Ovelity approved in Alzheimer's agitation, how does that embolden you guys to pursue even more indications? I'd imagine you can directly go to Phase 3 with Ovelity for other indications.”
“How should we think about the initial launch cadence in the first year?”
“One more on the guidance for this year, $150 to $170 at the midpoint, seems like that could be 35% to 40% year-over-year growth. And I believe you mentioned in the prepared remarks maybe volume grows by 10%, give or take, at the midpoint.”
Affiliation history
-
Jefferies
Analyst
Transcript header (unverified)
Current